Log in

DNLI Denali Therapeutics Inc. NASDAQ · United States

Denali Therapeutics (DNLI) news

Top story · Jul 28, 2026 · SEC filing 8-K

Denali Therapeutics completes an acquisition or sale of assets

Pursuant to the PRV Transfer Agreement, the Company received gross proceeds of $195.0 million from the buyer upon the closing of the Sale.

Source: 8-K filed Jul 28, 2026 on SEC EDGAR

Latest Denali Therapeutics news

We have not published a story on Denali Therapeutics yet. When there is news, it will appear here.

What Denali Therapeutics does

Denali Therapeutics is a biopharmaceutical company that aims to deliver biotherapeutics to the brain and the rest of the body. Its proprietary TransportVehicle (TV) technology is designed to cross the blood-brain barrier, carrying large molecules such as enzymes, oligonucleotides and antibodies to tissues after systemic administration. The company builds three TV franchises: Enzyme TV (ETV), Oligonucleotide TV (OTV) and Antibody TV (ATV). Its programs target rare diseases such as lysosomal storage disorders and common diseases such as Alzheimer's disease and Parkinson's disease. Its most advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for mucopolysaccharidosis II (MPS II), also called Hunter syndrome. The biologics license application for tividenofusp alfa is under priority review for accelerated approval by the FDA, with a PDUFA target action date of April 5, 2026. The clinical development portfolio also includes DNL126 for MPS IIIA, DNL593 for frontotemporal dementia-granulin, DNL628 for Alzheimer's disease and DNL952 for Pompe disease.

Product or programWhat it isStage
tividenofusp alfaEnzyme TV-enabled therapy for MPS II (Hunter syndrome)under priority review
DNL126TV-enabled candidate for MPS IIIA (Sanfilippo syndrome type A)clinical development
DNL593TV-enabled candidate for frontotemporal dementia-granulinclinical development
DNL628Oligonucleotide TV candidate for Alzheimer's diseaseclinical development

Summarised from the company's 10-K filed Feb 26, 2026.

Denali Therapeutics annual financials

LineFY2025FY2024
Revenue$0$0
Research and development$418.8 million$396.4 million
Net income (loss)-$512.5 million-$422.8 million
Cash from operations-$412.6 million-$347.7 million
Cash and equivalents$205.3 million$175.0 million
Short-term investments$662.6 million$657.4 million

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $201.5 million, plus short-term investments of $508.9 million, $710.5 million in all.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about Denali Therapeutics

What is the ticker symbol of Denali Therapeutics?

Denali Therapeutics Inc. trades under the ticker DNLI on NASDAQ.

Where is Denali Therapeutics listed?

Denali Therapeutics Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:4DN; LS:A2H9G8; LSX:A2H9G8.

What is the SEC CIK of Denali Therapeutics?

The SEC Central Index Key (CIK) for Denali Therapeutics Inc. is 1714899. Its filings are on SEC EDGAR.

How many shares does Denali Therapeutics have outstanding?

159,847,403 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06.

Which country or territory is Denali Therapeutics listed under?

Our directory records Denali Therapeutics Inc. under United States.

What does Denali Therapeutics do?

Our directory classifies Denali Therapeutics Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Denali Therapeutics?

The ISIN recorded for Denali Therapeutics Inc. is US24823R1059.

Does aibio.space cover Denali Therapeutics?

aibio.space lists Denali Therapeutics Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Denali Therapeutics incorporated?

SEC records list its state or country of incorporation as DE.

What does Denali Therapeutics develop?

Denali Therapeutics is a biopharmaceutical company that aims to deliver biotherapeutics to the brain and the rest of the body. Its proprietary TransportVehicle (TV) technology is designed to cross the blood-brain barrier, carrying large molecules such as enzymes, oligonucleotides and antibodies to tissues after systemic administration.

What is tividenofusp alfa from Denali Therapeutics?

tividenofusp alfa: Enzyme TV-enabled therapy for MPS II (Hunter syndrome) Stage: under priority review.

What is DNL126 from Denali Therapeutics?

DNL126: TV-enabled candidate for MPS IIIA (Sanfilippo syndrome type A) Stage: clinical development.

What was Denali Therapeutics's revenue last year?

$0 for the fiscal year ended Dec 31, 2025, as reported to the SEC.

Is Denali Therapeutics profitable?

Denali Therapeutics Inc. reported a net loss of $512.5 million for the fiscal year ended Dec 31, 2025, and used $412.6 million of cash in operations, per its annual report to the SEC.

How much does Denali Therapeutics spend on research and development?

$418.8 million in the fiscal year ended Dec 31, 2025, per its annual report.

Investor discussion: Denali Therapeutics

Members talk about Denali Therapeutics (DNLI). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Denali Therapeutics, newest first. Each line links the filing it comes from.

  1. Mergers

    Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,9.01). Source

  2. Distress

    Reported the end of a material agreement. SEC Form 8-K (Items 1.02,9.01). Source

  3. Financings

    Reported a financing. SEC Form 8-K (Items 2.03,7.01). Source

  4. Financings

    Reported a financing. SEC Form 8-K (Items 7.01,9.01). Source

  5. Financings

    Reported a financing. SEC Form 424B5. Source

  6. Financings

    Reported a financing. SEC Form 8-K (Items 1.01,5.07,9.01). Source

  7. Financings

    Reported a financing. SEC Form S-3ASR. Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:DNLI on TradingView.

SEC filings and registration

SEC name
Denali Therapeutics Inc.
CIK
1714899
Industry (SIC)
Biological Products, (No Diagnostic Substances) (2836)
US tickers
DNLI (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
Large accelerated filer
Business address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
Phone
(650) 866-8547
Shares outstanding
159,847,403 as of 2026-07-31 (10-Q filed 2026-08-06)

Recent filings (8-K and 6-K are the company's own announcements)

  • 10-Q filed 2026-08-06
  • 8-K filed 2026-08-06
  • 8-K filed 2026-07-28
  • 8-K filed 2026-06-18
  • 8-K filed 2026-06-04
  • 8-K filed 2026-05-22
  • 10-Q filed 2026-05-07
  • 8-K filed 2026-05-07

Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

Listing details

Denali Therapeutics Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker DNLI, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Denali Therapeutics Inc.
Ticker
DNLI
Listing
NASDAQ
Country or territory
United States
Business scope
Biotechnology
ISIN
US24823R1059
Other listed symbols
GETTEX:4DN; LS:A2H9G8; LSX:A2H9G8
Last quote in directory
2026-10-21
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.